Bi Asset Management Fondsmaeglerselskab A Immuno Gen, Inc. Transaction History

Bi Asset Management Fondsmaeglerselskab A

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$12.46 - $29.95 $539,069 - $1.3 Million	-43,264 Reduced 54.99%	35,409 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $1.05 Million - $1.48 Million	74,377 Added 1731.31%	78,673 $1.25 Million
Q2 2023 Aug 03, 2023	BUY	$3.75 - $20.05 $16,110 - $86,134	4,296 New	4,296 $81,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.